Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Bond Index Fund ETF vs Sana Biotechnology Inc — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.81, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Sana Biotechnology Inc is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | SANA | |
|---|---|---|
52-Week High | $49.91 | $5.92 |
52-Week Low | $47.57 | $2.68 |
Market Cap | — | $1.13B |
Sector | — | Health |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNDX trades at $47.82, up 0.06% on the day, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. Recent news highlights institutional activity, including Apella Capital reducing its stake and Archer Investment Management increasing holdings. The fund's dividend schedule shows consistent payouts, with the latest dividend of $0.12 scheduled for payment in August 2026.
The outlook for BNDX is cautious due to bearish technical indicators and mixed institutional sentiment. Risks include interest rate volatility and inflation concerns, as highlighted by recent Treasury yield movements. Opportunities lie in its role as a bond ETF providing diversified international fixed income exposure, but investors should weigh macroeconomic factors affecting bond markets.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
